Jacobs Levy Equity Management Inc. Takes $97,000 Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Jacobs Levy Equity Management Inc. purchased a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 19,869 shares of the company’s stock, valued at approximately $97,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KYTX. FMR LLC purchased a new stake in Kyverna Therapeutics during the third quarter valued at $33,000. Creative Planning purchased a new stake in Kyverna Therapeutics during the third quarter valued at $54,000. Federated Hermes Inc. purchased a new stake in Kyverna Therapeutics during the second quarter valued at $120,000. BNP Paribas Financial Markets increased its position in Kyverna Therapeutics by 2,166.4% during the third quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company’s stock valued at $133,000 after acquiring an additional 25,997 shares during the last quarter. Finally, Rhumbline Advisers purchased a new stake in Kyverna Therapeutics during the second quarter valued at $150,000. 18.08% of the stock is owned by institutional investors.

Kyverna Therapeutics Trading Down 5.6 %

NASDAQ:KYTX opened at $4.59 on Wednesday. Kyverna Therapeutics, Inc. has a 12-month low of $3.92 and a 12-month high of $35.06. The stock has a 50-day moving average price of $5.01 and a 200 day moving average price of $7.30.

Kyverna Therapeutics (NASDAQ:KYTX) last released its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.01. The business had revenue of $0.01 million for the quarter. On average, equities research analysts anticipate that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on KYTX shares. Rodman & Renshaw started coverage on Kyverna Therapeutics in a research report on Wednesday, October 9th. They set a “buy” rating and a $16.00 price objective for the company. Wells Fargo & Company reduced their price target on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. UBS Group initiated coverage on Kyverna Therapeutics in a research report on Thursday, October 10th. They issued a “buy” rating and a $13.00 price target for the company. Finally, HC Wainwright reduced their price target on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $25.71.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.